Literature DB >> 23475903

Enteroaggregative Escherichia coli strain in a novel weaned mouse model: exacerbation by malnutrition, biofilm as a virulence factor and treatment by nitazoxanide.

David T Bolick1, James K Roche1, Raquel Hontecillas2, Josep Bassaganya-Riera2, James P Nataro3, Richard L Guerrant1.   

Abstract

Enteroaggregative Escherichia coli (EAEC) is increasingly recognized as a common cause of diarrhoea in healthy, malnourished and immune-deficient adults and children. There is no reproducible non-neonatal animal model for longitudinal studies of disease mechanism or therapy. Using two strains of human-derived EAEC to challenge weaned C57BL/6 mice, we explored an in vivo model of EAEC infection in mice, in which disease was monitored quantitatively as the growth rate, stool shedding and tissue burden of organisms; nutritional status was varied, and a new class of therapeutics was assessed. A single oral challenge of EAEC strain 042 resulted in significant growth shortfalls (5-8 % of body weight in 12 days), persistent shedding of micro-organisms in stools [>10(3.2) c.f.u. (10 mg stool)(-1) for at least 14 days] and intestinal tissue burden [~10(3) c.f.u. (10 mg tissue)(-1) detectable up to 14 days post-challenge]. Moderate malnourishment of mice using a 'regional basic diet' containing 7 % protein and reduced fat and micronutrients heightened all parameters of infection. Nitazoxanide in subMIC doses, administered for 3 days at the time of EAEC challenge, lessened growth shortfalls (by >10 % of body weight), stool shedding [by 2-3 logs (10 mg stool)(-1)] and tissue burden of organisms (by >75 % in the jejunum and colon). Thus, weaned C57BL/6 mice challenged with EAEC is a convenient, readily inducible model of EAEC infection with three highly quantifiable outcomes in which disease severity is dependent on the nutritional status of the host, and which is modifiable in the presence of inhibitors of pyruvate ferredoxin oxidoreductase such as nitazoxanide.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23475903      PMCID: PMC3709553          DOI: 10.1099/jmm.0.046300-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  35 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Enteroaggregative Escherichia coli pathogenesis.

Authors:  James P Nataro
Journal:  Curr Opin Gastroenterol       Date:  2005-01       Impact factor: 3.287

Review 3.  Enteroaggregative Escherichia coli an emergent pathogen with different virulence properties.

Authors:  J M Villaseca; U Hernández; T R Sainz-Espuñes; C Rosario; C Eslava
Journal:  Rev Latinoam Microbiol       Date:  2005 Jul-Dec

4.  Diarrheagenic Escherichia coli infection in Baltimore, Maryland, and New Haven, Connecticut.

Authors:  James P Nataro; Volker Mai; Judith Johnson; William C Blackwelder; Robert Heimer; Shirley Tirrell; Stephen C Edberg; Christopher R Braden; J Glenn Morris; Jon Mark Hirshon
Journal:  Clin Infect Dis       Date:  2006-07-11       Impact factor: 9.079

5.  Quantitative biofilm assay using a microtiter plate to screen for enteroaggregative Escherichia coli.

Authors:  Naoko Wakimoto; Junichiro Nishi; Jalaluddin Sheikh; James P Nataro; Jav Sarantuya; Mayumi Iwashita; Kunihiro Manago; Koichi Tokuda; Masao Yoshinaga; Yoshifumi Kawano
Journal:  Am J Trop Med Hyg       Date:  2004-11       Impact factor: 2.345

6.  Association of putative enteroaggregative Escherichia coli virulence genes and biofilm production in isolates from travelers to developing countries.

Authors:  Jamal A Mohamed; David B Huang; Zhi-Dong Jiang; Herbert L DuPont; James P Nataro; Jaime Belkind-Gerson; Pablo C Okhuysen
Journal:  J Clin Microbiol       Date:  2006-11-08       Impact factor: 5.948

7.  Nitazoxanide inhibits biofilm production and hemagglutination by enteroaggregative Escherichia coli strains by blocking assembly of AafA fimbriae.

Authors:  Eliah R Shamir; Michelle Warthan; Sareena P Brown; James P Nataro; Richard L Guerrant; Paul S Hoffman
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

8.  Studies with enteroaggregative Escherichia coli in the gnotobiotic piglet gastroenteritis model.

Authors:  S Tzipori; J Montanaro; R M Robins-Browne; P Vial; R Gibson; M M Levine
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

9.  Characterization of enteroadherent-aggregative Escherichia coli, a putative agent of diarrheal disease.

Authors:  P A Vial; R Robins-Browne; H Lior; V Prado; J B Kaper; J P Nataro; D Maneval; A Elsayed; M M Levine
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

Review 10.  Malnutrition as an enteric infectious disease with long-term effects on child development.

Authors:  Richard L Guerrant; Reinaldo B Oriá; Sean R Moore; Mônica O B Oriá; Aldo A M Lima
Journal:  Nutr Rev       Date:  2008-09       Impact factor: 7.110

View more
  22 in total

1.  Protein Malnutrition Alters Tryptophan and Angiotensin-Converting Enzyme 2 Homeostasis and Adaptive Immune Responses in Human Rotavirus-Infected Gnotobiotic Pigs with Human Infant Fecal Microbiota Transplant.

Authors:  David D Fischer; Sukumar Kandasamy; Francine C Paim; Stephanie N Langel; Moyasar A Alhamo; Lulu Shao; Juliet Chepngeno; Ayako Miyazaki; Huang-Chi Huang; Anand Kumar; Gireesh Rajashekara; Linda J Saif; Anastasia N Vlasova
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

2.  Protein-energy malnutrition alters IgA responses to rotavirus vaccination and infection but does not impair vaccine efficacy in mice.

Authors:  Elizabeth A Maier; Kristina J Weage; Marjorie M Guedes; Lee A Denson; Monica M McNeal; David I Bernstein; Sean R Moore
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

Review 3.  The Burden of Enteropathy and "Subclinical" Infections.

Authors:  Elizabeth T Rogawski; Richard L Guerrant
Journal:  Pediatr Clin North Am       Date:  2017-08       Impact factor: 3.278

4.  The micronutrient zinc inhibits EAEC strain 042 adherence, biofilm formation, virulence gene expression, and epithelial cytokine responses benefiting the infected host.

Authors:  Pedro Medeiros; David T Bolick; James K Roche; Francisco Noronha; Caio Pinheiro; Glynis L Kolling; Aldo Lima; Richard L Guerrant
Journal:  Virulence       Date:  2013-08-19       Impact factor: 5.882

Review 5.  Small Molecules That Sabotage Bacterial Virulence.

Authors:  Benjamin K Johnson; Robert B Abramovitch
Journal:  Trends Pharmacol Sci       Date:  2017-02-14       Impact factor: 14.819

6.  Zinc deficiency alters host response and pathogen virulence in a mouse model of enteroaggregative Escherichia coli-induced diarrhea.

Authors:  David T Bolick; Glynis L Kolling; John H Moore; Luís Antônio de Oliveira; Kenneth Tung; Casandra Philipson; Monica Viladomiu; Raquel Hontecillas; Josep Bassaganya-Riera; Richard L Guerrant
Journal:  Gut Microbes       Date:  2014

Review 7.  Impact of Childhood Malnutrition on Host Defense and Infection.

Authors:  Marwa K Ibrahim; Mara Zambruni; Christopher L Melby; Peter C Melby
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

8.  Nitazoxanide Inhibits Pilus Biogenesis by Interfering with Folding of the Usher Protein in the Outer Membrane.

Authors:  Peter Chahales; Paul S Hoffman; David G Thanassi
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

9.  Defined Nutrient Diets Alter Susceptibility to Clostridium difficile Associated Disease in a Murine Model.

Authors:  John H Moore; Caio C D Pinheiro; Edna I Zaenker; David T Bolick; Glynis L Kolling; Edward van Opstal; Francisco J D Noronha; Pedro H Q S De Medeiros; Raphael S Rodriguez; Aldo A Lima; Richard L Guerrant; Cirle A Warren
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

Review 10.  Advances in understanding Giardia: determinants and mechanisms of chronic sequelae.

Authors:  Luther A Bartelt; R Balfour Sartor
Journal:  F1000Prime Rep       Date:  2015-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.